Vontobel Holding Ltd. Buys 2,677 Shares of Kenvue Inc. (NYSE:KVUE)

Vontobel Holding Ltd. lifted its position in Kenvue Inc. (NYSE:KVUE) by 13.4% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 22,594 shares of the company’s stock after buying an additional 2,677 shares during the quarter. Vontobel Holding Ltd.’s holdings in Kenvue were worth $523,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. Cornerstone Wealth Group LLC lifted its stake in Kenvue by 176.2% in the 1st quarter. Cornerstone Wealth Group LLC now owns 350,371 shares of the company’s stock worth $7,519,000 after purchasing an additional 223,537 shares in the last quarter. Janney Montgomery Scott LLC increased its holdings in shares of Kenvue by 56.2% in the first quarter. Janney Montgomery Scott LLC now owns 1,840,875 shares of the company’s stock worth $39,505,000 after purchasing an additional 662,666 shares during the period. BI Asset Management Fondsmaeglerselskab A S purchased a new stake in shares of Kenvue in the first quarter worth $1,050,000. Norden Group LLC bought a new stake in Kenvue during the first quarter valued at $1,792,000. Finally, Lorne Steinberg Wealth Management Inc. grew its position in Kenvue by 59.0% during the second quarter. Lorne Steinberg Wealth Management Inc. now owns 154,690 shares of the company’s stock worth $2,812,000 after buying an additional 57,375 shares in the last quarter. 97.64% of the stock is currently owned by institutional investors.

Kenvue Price Performance

Shares of NYSE:KVUE opened at $22.93 on Tuesday. The company has a quick ratio of 0.68, a current ratio of 0.99 and a debt-to-equity ratio of 0.69. The stock has a market cap of $43.91 billion, a PE ratio of 29.40, a PEG ratio of 2.76 and a beta of 1.40. The company’s fifty day moving average is $22.30 and its 200 day moving average is $20.22. Kenvue Inc. has a 52 week low of $17.67 and a 52 week high of $23.55.

Kenvue (NYSE:KVUE) last released its quarterly earnings data on Tuesday, August 6th. The company reported $0.32 EPS for the quarter, topping the consensus estimate of $0.28 by $0.04. The firm had revenue of $4 billion for the quarter, compared to the consensus estimate of $3.93 billion. Kenvue had a return on equity of 21.80% and a net margin of 7.23%. The company’s quarterly revenue was down .3% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.32 earnings per share. Research analysts anticipate that Kenvue Inc. will post 1.08 earnings per share for the current year.

Kenvue Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, November 27th. Stockholders of record on Wednesday, November 13th will be paid a dividend of $0.205 per share. This represents a $0.82 dividend on an annualized basis and a dividend yield of 3.58%. The ex-dividend date of this dividend is Wednesday, November 13th. Kenvue’s dividend payout ratio (DPR) is presently 105.13%.

Analyst Ratings Changes

Several analysts have weighed in on KVUE shares. JPMorgan Chase & Co. raised their price target on Kenvue from $24.00 to $25.00 and gave the company an “overweight” rating in a report on Friday, October 11th. UBS Group raised their target price on shares of Kenvue from $20.00 to $22.00 and gave the company a “neutral” rating in a research note on Wednesday, August 7th. Piper Sandler lifted their target price on shares of Kenvue from $20.00 to $21.00 and gave the company a “neutral” rating in a research report on Monday, September 23rd. Jefferies Financial Group assumed coverage on shares of Kenvue in a report on Tuesday, September 24th. They issued a “buy” rating and a $27.00 price target on the stock. Finally, Deutsche Bank Aktiengesellschaft lifted their price objective on shares of Kenvue from $23.00 to $24.00 and gave the stock a “buy” rating in a report on Wednesday, August 7th. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $22.20.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.